Posted on

Medspresso Coffee Webinar Now Available for Viewing

Medspresso Coffee Webinar Now Available for Viewing

CAPE TOWN, SA / ACCESSWIRE / December 7, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Medspresso™ is delighted to share the recorded version of the coffee webinar The Art, Craft, and Science of Coffee held December 01, 2021 is now available for viewing and can be found here. The webinar panelists include internationally renowned barista and roaster Gerald Charles from Rock ‘n Roller Coffee, Alessandro Morrico CEO of Morrico Import Export, a specialist coffee equipment importer, distributor, and consulting company in South Africa, and Michael Sachar, CEO of M2Bio Food and Beverage, with over 20 years of experience trading in raw and roasted coffee beans around the world. The event was moderated by M2Bio Sciences CEO, Jeff Robinson.

Watch the webinar here. Download the presentation here.

In addition, Medspresso™ is hosting a coffee tasting at Zootly in Cape Town. The event details are as follows:

Zootly

73 Kloof St, Gardens, Cape Town, 8001
Friday, December 10, 2021
10:00 am to 13:00 pm – SAST

Specialty coffee, tea, hot chocolate, and Medspresso™ Torro Espresso Machines will all be available for trial and tasting. The coffee tasting is structured to allow everyone to get the best of the Medspresso™ range of products.

“Zootly is one of our longest-standing partners and we are looking forward to welcoming and delighting a host of new Medspresso™ CBD Infused beverage consumers this coming Friday. Popularity around our coffee tastings have caught on like wildfire and we expect a big turnout. We share a common belief in the power of CBD, and feel that adding CBD to one’s daily routine is more important now than ever.” says Michael Sachar.

‘’The response to our Medspresso and Liviana products has been exceptional. We have partnered with 12 new stockists over the past 2 weeks, giving us a total of 78 clients in South Africa. We are overjoyed with the growth rate of our products, and look forward to further shared success in 2022.” added Jeff Robinson.

About Wuhan General Group, Inc./M2Bio Sciences, Inc.

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co
Follow us on Twitter: https://twitter.com/Medspresso
Follow us on TikTok: https://www.tiktok.com/@Medspresso
Follow us on Facebook: https://www.facebook.com/Medspresso
Follow us on YouTube: https://www.youtube.com/channel/Medspresso
Follow us on Instagram: https://www.instagram.com/Medspresso.official

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/676324/Medspresso-Coffee-Webinar-Now-Available-for-Viewing

Posted on

Wuhan General Group Inc Cancels 5,000,000 Common Shares

Wuhan General Group Inc Cancels 5,000,000 Common Shares

CAPE TOWN, SA / ACCESSWIRE / November 22, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:

Logo Description automatically generated

M2Bio Sciences is pleased to announce that 5,000,000 common shares held by the previous CEO have been cancelled. The company has reduced its share capital by 9%. The total number of issued common shares is now 50,999,662. (previously 55,999,662).

M2Bio Sciences CEO and Founder Jeff Robinson explains “In our continued efforts to clean up the capital structure of the company and in preparation for a nifty and rewarding 2022, this is merely baby step number one. We are looking forward to executing and delivering by leaps and bounds in the near future.”

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

For further information:

Publicly traded company (OTC PINK:WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co
Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Follow us on Instagram: https://www.instagram.com/m2bio.sciences

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc

View source version on accesswire.com:
https://www.accesswire.com/674049/Wuhan-General-Group-Inc-Cancels-5000000-Common-Shares

Posted on

The New Multi Capsule “Medspresso Torro” Gets Unleashed

The New Multi Capsule “Medspresso Torro” Gets Unleashed

CAPE TOWN, SA / ACCESSWIRE / November 4, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Medspresso™ is pleased to announce the launch of the new Medspresso™ Torro Dual Purpose Home Espresso Maker. The new design is unique in that it’s one of very few capsule systems that accommodate both Dolcé Gusto® and Nespresso® size capsules. The machine is a welcome addition to the existing Medspresso product range.

The Torro is available immediately for purchase on the Medspresso website and will roll into preferred retailers across South Africa just in time for the festive season. In addition to the South African market, there are plans for export to international online retailers like Amazon UK, US, and DE. Other exciting markets that are being considered are the Middle East, South America, the Far East, and Australasia.

CEO and Founder of M2Bio™ Jeff Robinson explains: “We are very excited for the launch of this amazing delivery system. The South African capsule market has massive potential for growth and this offering will give consumers the choice of preferred capsule and beverage in the comfort of their homes. There are already 75 different capsule beverages available in both Dolcé Gusto® and Nespresso® size capsules to choose from and this machine can accommodate both, opening up a new world of coffee for consumers. Capsule coffee and beverages have come a long way since Nespresso® launched their systems, the new paradigm shift is towards sustainability, capsule biodegradability, and recycling. Nespresso® has a great recycling program for consumers and our Medspresso™ range is proudly fully biodegradable, our consumers can enjoy their favorite coffees with a clear conscience.”

The powerful Torro machine features a 19-Bar pressure pump, serving up a coffee in as little as 25 seconds, and users can choose between a small or large cup. The machine comes with easily programmable functions, bringing a personalized barista-style coffee experience into your home. The drip tray is adjustable in height to suit everything from tiny espresso cups to taller mugs. It’s small, streamlined, and sleek-looking too. It looks smart on any kitchen worktop or office space without taking up too much roo

Grab your machine now.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co
Follow us on Twitter: https://twitter.com/Medspresso
Follow us on Facebook: https://www.facebook.com/Medspresso
Follow us on YouTube: https://www.youtube.com/channel/Medspresso
Follow us on Instagram: https://www.instagram.com/medspresso.official

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

 

View source version on accesswire.com:
https://www.accesswire.com/671187/The-New-Multi-Capsule-Medspresso-Torro-Gets-Unleashed

Posted on

Medspress(TM) Announces Webinar: The Art, Craft, and Science of Coffee

Medspress(TM) Announces Webinar: The Art, Craft, and Science of Coffee

CAPE TOWN, SA / ACCESSWIRE / November 1, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:

Medspresso™ is pleased to announce its live coffee webinar is scheduled for Friday, 12 November 2021 at 15:00 SAST. The webinar will feature a panel of coffee experts with decades’ worth of experience and expertise in everything from growing, roasting, brewing, and appraising coffee. The panel will dive into the current state of the coffee market and further discuss the art, craft, and science of the bean-to-cup journey and everything in-between. The esteemed panel includes Gerald Charles, Alessandro Morrico, and Michael Sachar, and is chaired by Jeff Robinson.

“Every day, millions of people around the world begin their day with a cup of coffee. Some chug it as vital fuel to get them through their day, and some savor it carefully as part of their morning ritual. For most, coffee is just a drink, but not for us. For us, it’s an art, a craft and a passion. Our devotion to coffee has taken us all over the world in the search for the finest beans. Join us for an exciting conversation exploring the history of coffee, the art of roasting, and a deep dive into the world of specialty coffee.” Michael Sachar explains.

The panel of experts will include award-winning, internationally renowned barista and roaster Gerald Charles from Rock ‘n Roller Coffee. Gerald has been involved in the South African coffee industry for over 18 years and his technical knowledge surrounding coffee and the intricacies of roasting the perfect bean is unparalleled.

Also joining the panel is Alessandro Morrico CEO of Morrico Import Export, a specialist coffee equipment importer, distributor, and coffee consulting company in South Africa. Alessandro holds an SCAE Diploma (Specialty Coffee Association of America and Europe) and is one of very few Q Graders in South Africa, meaning he has mastered the ins and outs of everything coffee. He is Vice Chairman of the Speciality Coffee Association of South Africa (SCASA) and has been Barista Championship Head Judge for over 10 years. He was certified for the World Barista Championship from 2009 to 2011. In short, Alessandro knows his beans.

Michael Sachar, the third panelist and CEO of M2Bio Food and Beverage, possesses an extraordinary amount of experience having worked in the USA, China, and the Middle East trading in raw and roasted coffee beans for 20 years. He has a very keen eye and taste for consumer demands and behavior. Michael will share his knowledge on the health benefits of the CBD and coffee combination, and lift the veil on how coffee enthusiasts can bring the world-class specialty coffee taste and experience into their homes.

To attend the webinar sign up here.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)

Website: www.m2bio.co

E-mail: info@m2bio.co

Follow us on Twitter: https://twitter.com/Medspresso

Follow us on Facebook: https://www.facebook.com/Medspresso

Follow us on YouTube: https://www.youtube.com/channel/Medspresso

Follow us on Instagram: https://www.instagram.com/medspresso.official

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/670516/MedspressTM-Announces-Webinar-The-Art-Craft-and-Science-of-Coffee